TG 01 - Targovax

Drug Profile

TG 01 - Targovax

Alternative Names: TG-01 - Targovax

Latest Information Update: 07 Jun 2016

Price : $50

At a glance

  • Originator Norsk Hydro; Norwegian Radium Hospital
  • Developer Targovax
  • Class Antineoplastics; Cancer vaccines; Peptide vaccines
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pancreatic cancer

Most Recent Events

  • 14 Apr 2016 Interim immunogenicity data from a phase I/II trial in Pancreatic cancer released by Targovax
  • 09 Mar 2015 Targovax plans expansion of a phase I/II trial for Pancreatic cancer in UK and Norway (NCT02261714)
  • 01 Dec 2014 Targovax completes enrolment in its phase IIa (of phase I/IIa) trial for Pancreatic cancer (Adjuvant therapy, Combination therapy) in United Kingdom and Norway (NCT02261714)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top